Richter, SS, et al.
Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999–2011. Emerging Infectious Diseases
2013; 7: 1074–1083.
Whitney, CG. Changing epidemiology of pneumococcal disease in the era of conjugate vaccines. Current Epidemiology Reports
2016; 3: 125–135.
Weinberger, DM, Malley, R, Lipsitch, M. Serotype replacement in disease following pneumococcal vaccination: a discussion of the evidence. Lancet
2011; 378: 1962–1973.
Geno, KA, et al.
Pneumococcal capsules and their types: past, present, and future. Clinical Microbiology Reviews
2015; 28: 871–899.
Waight, PA, et al.
Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infectious Diseases
2015; 15: 535–543.
van der Linden, M, et al.
Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children. Vaccine
2014; 30: 5880–5885.
van der Linden, M, et al.
Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany. PLoS ONE
2015; 10: e0131494.
Moore, MR, et al.
Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infectious Diseases
2015; 15: 301–309.
Regev-Yochay, G, et al.
Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: a nationwide surveillance study. Vaccine
2015; 33: 1135–1142.
Steens, A, Vestrheim, DF, de Blasio, BF. Pneumococcal vaccination in older adults in the era of childhood vaccination: public health insights from a Norwegian statistical prediction study. Epidemics
2015; 11: 24–31.
Harboe, ZB, et al.
Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clinical Infectious Diseases
2014; 59: 1066–1073.
Castiglia, P. Recommendations for pneumococcal immunization outside routine childhood immunization programs in western Europe. Advances in Therapy
2014; 31: 1011–1044.
Williams, WW, et al.
Surveillance of vaccination coverage among adult populations — United States, 2014. Morbidity and Mortality Weekly Report
2016; 1: 1–36.
Hausdorff, WP, Hanage, WP. Interim results of an ecological experiment – conjugate vaccination against the pneumococcus and serotype replacement. Human Vaccines and Immunotherapeutics
2016; 12: 358–374.
Feikin, DR, et al.
Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Medicine
2013; 10: e1001517.
Tin Tin Htar, M, Christopoulou, D, Schmitt, HJ. Pneumococcal serotype evolution in Western Europe. BMC Infectious Diseases
2015; 15: 1–10.
Harboe, ZB, et al.
pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark. PLoS ONE
2013; 8: e51460.
Giese, C, et al.
Low vaccination coverage for seasonal influenza and pneumococcal disease among adults at-risk and health care workers in Ireland, 2013: the key role of GPs in recommending vaccination. Vaccine
2016; 34: 3657–3662.
Theidel, U, Kuhlmann, A, Braem, A. Pneumococcal vaccination rates in adults in Germany. Deutsches Ärzteblatt International
2013; 110: 743–750.
Bonten, MJM, et al.
Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. New England Journal of Medicine
2015; 372: 1114–1125.
Patterson, S, et al.
A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia immunization Trial in Adults). Trials in Vaccinology
2016; 5: 92–96.
Andrews, NJ, et al.
Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine
2012; 30: 6802–6808.
Jackson, LA, et al.
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine
2013; 31: 3577–3584.
Jackson, LA, et al.
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine
2013; 31: 3585–3593.
Tomczyk, S, et al.
Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ⩾65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report
2014; 37: 822–825.
European Commission. Amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council. Section L159/72. Official Journal of the European Union. 2002 [June 2016]. Available from: http://ec.europa.eu/health/ph_threats/com/docs/1589_2008_en.pdf.
Vickers, I, O'Flanagan, D, Cafferkey, M, Humphreys, H. Multiplex PCR to determine Streptococcus pneumoniae serotypes causing otitis media in the Republic of Ireland with further characterisation of antimicrobial susceptibilities and genotypes. European Journal of Clinical Microbiology and Infectious Diseases
2011; 30: 447–453.
Wayne, P. Performance standards for antimicrobial susceptibility testing; twenty-third information supplement. CLSI document. M100-S23. Clinical Laboratory Standards Institute 2013.
Bedford, D, et al.
The acceptability of pneumococcal vaccine to older persons in Ireland. Irish Medical Journal
2000; 93: 48–49.
Kyaw, MH, et al.
Adults with invasive pneumococcal disease. American Journal of Preventive Medicine
2006 2015/11/27; 31: 286–292.
Tramuto, F. et al.
Pneumococcal colonization in the familial context and implications for anti-pneumococcal immunization in adults: results from the BINOCOLO project in Sicily. International Journal of Molecular Sciences
2017; 18: 105.
Moffitt, K, Malley, R. Rationale and prospects for novel pneumococcal vaccines. Human Vaccines and Immunotherapeutics
2016; 12: 383–392.